Bicycle Therapeutics (NASDAQ:BCYC) Hits New 1-Year Low – Should You Sell?

Bicycle Therapeutics plc (NASDAQ:BCYC) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as $9.89 and last traded at $10.13, with a volume of 3986 shares trading hands. The stock had previously closed at $10.23.

Analysts Set New Price Targets

BCYC has been the topic of a number of research analyst reports. JMP Securities decreased their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Tuesday. B. Riley decreased their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Stephens restated an “equal weight” rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.14.

Bicycle Therapeutics Trading Up 4.2 %

The company’s 50 day simple moving average is $12.68 and its 200 day simple moving average is $18.75. The stock has a market capitalization of $704.27 million, a PE ratio of -3.10 and a beta of 1.12.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.10. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s quarterly revenue was down 30.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.16) earnings per share. As a group, analysts predict that Bicycle Therapeutics plc will post -3.06 EPS for the current year.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, Director Bros. Advisors Lp Baker bought 985,397 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were acquired at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the purchase, the director now owns 9,537,643 shares in the company, valued at approximately $131,237,967.68. The trade was a 11.52 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin Lee sold 9,038 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares of the company’s stock, valued at approximately $6,974,916.34. This trade represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,677 shares of company stock worth $392,413 in the last quarter. 8.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. raised its stake in shares of Bicycle Therapeutics by 406.2% in the 4th quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company’s stock valued at $63,769,000 after purchasing an additional 3,655,101 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Bicycle Therapeutics by 43.3% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 80,236 shares of the company’s stock worth $1,123,000 after acquiring an additional 24,260 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Bicycle Therapeutics in the 4th quarter valued at approximately $2,475,000. Fcpm Iii Services B.V. boosted its holdings in Bicycle Therapeutics by 47.5% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company’s stock worth $48,333,000 after purchasing an additional 1,112,369 shares during the period. Finally, Caption Management LLC bought a new position in shares of Bicycle Therapeutics during the fourth quarter valued at approximately $2,283,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.